Ka-Won Kang

List of Publications by Year
in descending order

45	487	1040056	713466
papers	citations	9	21
		h-index	g-index

48	48	48	714
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Postoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea. Journal of Clinical Medicine, 2022, 11, 1477.	2.4	1
2	Generation of a human induced pluripotent stem cell line KUMi006 from a patient with multiple myeloma. Stem Cell Research, 2022, 61, 102767.	0.7	0
3	PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma. Biomedicines, 2022, 10, 1099.	3.2	2
4	A Proteomic Approach to Understand the Clinical Significance of Acute Myeloid Leukemia–Derived Extracellular Vesicles Reflecting Essential Characteristics of Leukemia. Molecular and Cellular Proteomics, 2021, 20, 100017.	3.8	8
5	Dual size-exclusion chromatography for efficient isolation of extracellular vesicles from bone marrow derived human plasma. Scientific Reports, 2021, 11, 217.	3.3	7
6	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Annals of Hematology, 2021, 100, 2051-2059.	1.8	6
7	Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma. Frontiers in Oncology, 2021, 11, 669817.	2.8	6
8	Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients. Frontiers in Oncology, 2021, 11, 687361.	2.8	0
9	Generation of induced pluripotent stem cell line KUMi002-A with normal karyotype from a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Stem Cell Research, 2021, 55, 102465.	0.7	0
10	CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells. Biochemical Pharmacology, 2021, 190, 114658.	4.4	7
11	Generation of the induced pluripotent stem cell line KUMi001-A carrying the Philadelphia chromosome from a chronic myeloid leukemia patient. Stem Cell Research, 2021, 55, 102464.	0.7	0
12	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. Scientific Reports, 2021, 11, 18449.	3.3	3
13	Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. Journal of Clinical Medicine, 2021, 10, 4774.	2.4	2
14	GCC2 as a New Early Diagnostic Biomarker for Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5482.	3.7	9
15	The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma. Korean Journal of Internal Medicine, 2021, 36, 1459-1470.	1.7	0
16	Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. Scientific Reports, 2020, 10, 39.	3.3	13
17	CXCR2 Ligands and mTOR Activation Enhance Reprogramming of Human Somatic Cells to Pluripotent Stem Cells. Stem Cells and Development, 2020, 29, 119-132.	2.1	13
18	Supporting data on enhanced reprogramming of human CD34+ hematopoietic stem cells to induced pluripotent stem cells using human placenta-derived cell conditioned medium. Data in Brief, 2020, 32, 106140.	1.0	1

#	Article	IF	Citations
19	Generation of an induced pluripotent stem cell line KUMCi001-A from CD34+ bone marrow cells of a patient with acute lymphoblastic leukemia using human placenta-derived cell conditioned medium. Stem Cell Research, 2020, 47, 101913.	0.7	3
20	PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Scientific Reports, 2020, 10, 12641.	3.3	20
21	Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. Therapeutic Advances in Hematology, 2020, 11, 204062072096688.	2.5	2
22	Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation. Stem Cell Research, 2020, 49, 102030.	0.7	5
23	Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab. Annals of Hematology, 2020, 99, 1493-1503.	1.8	2
24	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). Therapeutic Advances in Hematology, 2020, 11, 204062072092104.	2.5	2
25	Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim. Cancer Medicine, 2020, 9, 6102-6110.	2.8	7
26	Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization. BMC Cancer, 2020, 20, 619.	2.6	6
27	Early-Stage Lung Cancer Diagnosis by Deep Learning-Based Spectroscopic Analysis of Circulating Exosomes. ACS Nano, 2020, 14, 5435-5444.	14.6	248
28	Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia. Korean Journal of Internal Medicine, 2020, 35, 970-978.	1.7	6
29	The role of platelet function analyzer-200 in predicting perioperative bleeding risk. Korean Journal of Internal Medicine, 2020, 35, 1199-1209.	1.7	7
30	Single‐dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. Journal of Clinical Apheresis, 2019, 34, 579-588.	1.3	9
31	Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. Korean Journal of Internal Medicine, 2019, 34, 1333-1346.	1.7	3
32	Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea. Blood, 2019, 134, 2951-2951.	1.4	0
33	Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab. Blood, 2019, 134, 2227-2227.	1.4	1
34	The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker. Anticancer Research, 2018, 38, 3935-3942.	1.1	19
35	Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. PLoS ONE, 2018, 13, e0192656.	2.5	2
36	One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea. Blood, 2018, 132, 3347-3347.	1.4	0

#	Article	IF	Citations
37	Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. Leukemia Research, 2017, 57, 1-8.	0.8	6
38	Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. Korean Journal of Internal Medicine, 2017, 32, 711-721.	1.7	19
39	CXCR2 Inhibition in Human Pluripotent Stem Cells Induces Predominant Differentiation to Mesoderm and Endoderm Through Repression of mTOR, Î²-Catenin, and hTERT Activities. Stem Cells and Development, 2016, 25, 1006-1019.	2.1	23
40	Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy. Blood, 2016, 128, 3041-3041.	1.4	0
41	A Case of Primary Cardiac Osteosarcoma with Pulmonary Vein Obstruction. Korean Journal of Medicine, 2015, 89, 233-237.	0.3	0
42	Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies. Blood, 2015, 126, 4889-4889.	1.4	0
43	High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia. Blood, 2015, 126, 4890-4890.	1.4	0
44	Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer. Chemotherapy, 2014, 60, 91-98.	1.6	10
45	Bladder and Liver Involvement of Visceral Larva Migrans May Mimic Malignancy. Cancer Research and Treatment, 2014, 46, 419-424.	3.0	7